Abstract: Multispecific antibodies that specifically bind at least two different epitopes are provided. Structural variants of native antibodies (antibody analogs) are also provided. Also provided are multispecific antibodies and antibody analogs having a range of biological activities. Agonist and antagonist multispecific antibodies and agonist and antagonist antibody analogs are provided. Multispecific antibodies and antibody analogs conjugated with therapeutic and/or diagnostic agents are also provided, as are multispecific antibodies and antibody analogs conjugated with agents to increase in vivo half-life compared to multispecific antibodies and antibody analogs lacking such agents. In addition, methods of making multispecific antibodies and antibody analogs and compositions comprising multispecific antibodies and antibody analogs are provided. Therapeutic, research, and diagnostic uses of multispecific antibodies and antibody analogs are also provided.

Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: Multispecific antibodies that specifically bind at least two different epitopes are provided. Structural variants of native antibodies (antibody analogs) are also provided. Also provided are multispecific antibodies and antibody analogs having a range of biological activities. Agonist and antagonist multispecific antibodies and agonist and antagonist antibody analogs are provided. Multispecific antibodies and antibody analogs conjugated with therapeutic and/or diagnostic agents are also provided, as are multispecific antibodies and antibody analogs conjugated with agents to increase in vivo half-life compared to multispecific antibodies and antibody analogs lacking such agents. In addition, methods of making multispecific antibodies and antibody analogs and compositions comprising multispecific antibodies and antibody analogs are provided. Therapeutic, research, and diagnostic uses of multispecific antibodies and antibody analogs are also provided.

Abstract: Chimeric heteromultimer adhesins that bind the ligand of natural heromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of the ErbB2 and ErbB3 and ErbB2 and ErbB4. The chimeric ErB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.

Abstract: Methods are presented for microwave assisted, enzymatic deglycosylation of proteins. The rate at which deglycosylation is achieved and without protein degradation facilitates rapid and accurate molecular weight determination by mass spectrometry.

Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.

Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.

Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-? and heregulin 2-?, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-? has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-? useful in the production of heregulin 2-? by recombinant means. Further provided an amino acid sequence of heregulin 2-? and heregulin 2-?. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: Methods are presented for microwave assisted, enzymatic deglycosylation of proteins. The rate at which deglycosylation is achieved and without protein degradation facilitates rapid and accurate molecular weight determination by mass spectrometry.

Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-? and heregulin 2-?, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-? has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-? useful in the production of heregulin 2-? by recombinant means. Further provided an amino acid sequence of heregulin 2-? and heregulin 2-?. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.

Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.

Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.

Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-&agr; and heregulin 2-&bgr;, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-&agr; has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-&agr; useful in the production of heregulin 2-&agr; by recombinant means. Further provided an amino acid sequence of heregulin 2-&agr; and heregulin 2-&bgr;. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: Novel polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-&agr; and heregulin 2-&bgr;, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-&agr; has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-&agr; useful in the production of heregulin 2-&agr; by recombinant means. Further provided an amino acid sequence of heregulin 2-&agr; and heregulin 2-&bgr;. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.